ABPI Statutory Scheme consultation response 2024 Executive summary

The ABPI's April 2024 response to the Department of Health and Social Care's consultation on branded medicine pricing supports scheme alignment with VPAG in principle but opposes retaining the 2% growth rate as unsustainable, contests payment rate proposals, and warns the 35% price-decline threshold risks supply disruption. Unlike VPAG, the Statutory Scheme lacks dialogue mechanisms to monitor consequences.